Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
AB Sciex
RANDOX LABORATORIES

Test Improves Diagnosis of Tuberculous Meningitis in HIV Patients

By Labmedica International staff writers
Posted on 07 Nov 2013
Image: The Xpert MTB/RIF cartridge for diagnosing tuberculosis to be used on the GeneXpert System (Photo courtesy of Cepheid).
Image: The Xpert MTB/RIF cartridge for diagnosing tuberculosis to be used on the GeneXpert System (Photo courtesy of Cepheid).
Tuberculous meningitis (TBM) is a serious and often fatal illness that is difficult to diagnose particularly in resource-poor areas and is especially common in individuals infected with the human immunodeficiency virus (HIV).

A newly available DNA test that can be used in these resource-poor settings and is generally used to detect Mycobacterium tuberculosis (TB), the causative organism, in sputum, and to detect TB DNA in cerebrospinal fluid, has been evaluated for TBM.

Microbiologists at the University of KwaZulu-Natal (Durban, South Africa) performed an evaluation study in 204 South African patients with a meningeal-like illness, of whom 87% were HIV-infected. In this cohort, using a gold standard of positive culture or traditional polymerase chain reaction (PCR) to determine who truly had TBM, 59 individuals had definite TBM, 64 had probable TBM, and 81 did not have TBM. These patients were recruited from hospitals in South Africa between January 2008 and December 2011.

The newly available test was the Xpert MTB/RIF (Cepheid; Sunnyvale, CA, USA) which is an integrated automated sample-processing and real-time PCR platform developed to simultaneously detect M. tuberculosis and rifampicin resistance in a single-use-cartridge hands-free step. The sensitivity of Xpert MTB/RIF was significantly better than that of smear microscopy (62% versus 12%) and significantly better than that of clinical signs (CS) (62% versus 30%) The sensitivity of the Xpert MTB/RIF was higher when centrifuged versus uncentrifuged samples were used (82% versus 47%). The test did not perform as well in the few individuals who were not HIV-infected.

The Xpert MTB/RIF test correctly identified more positive cases than the other tests used to diagnose TB meningitis, within 24 hours of first seeing a patient. However, the test accuracy was more robust when the cerebrospinal fluid sample was centrifuged to achieve the best results. This means additional apparatus would be required, resulting in higher cost and requiring more training. The scientists concluded that this test could still be useful in settings where resources are limited.

The authors concluded that Xpert MTB/RIF might be a good rule-in test for the diagnosis of TBM in HIV-infected individuals from a tuberculosis-endemic setting, particularly when a centrifuged CSF pellet is used. Further studies are required to confirm these findings in different settings. The study was published on October 22, 2013, in the journal Public Library of Science Medicine.

Related Links:

University of KwaZulu-Natal
Cepheid



ADVANCED INSTRUMENTS
GREINER-BIO-ONE
PURITAN MEDICAL
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.